Altimmune, Inc. (ALT) vs Nuvectis Pharma, Inc. (NVCT)
A side-by-side comparison of Altimmune, Inc. and Nuvectis Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALT
Altimmune, Inc.
$2.66HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
NVCT
Nuvectis Pharma, Inc.
$20.36HealthcareDelayed quote: Oct 6, 2026, 12:53 PM EDT
Total return — ALT vs NVCT
growth of $100 · dividends reinvested · last 5yALT -65.1% (-19.0%/yr)NVCT +558.2% (+45.8%/yr)NVCT compounded faster over this window
Log scale — wide-divergence pair
ALT NVCT
ALT vs NVCT: by the numbers
- •NVCT is the larger company ($540M vs $517M market cap).
- •Both run net losses; NVCT's is the smaller (0.00% vs -296000.00% net margin).
Metrics side by side
Valuation
| Metric | ALT | NVCT |
|---|---|---|
| P/S ratio | 16680.22 | N/A |
| P/B ratio | 1.09 | 59.49 |
Profitability
| Metric | ALT | NVCT |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -230460.98% | 0.00% |
| Net margin | -296000.00% | 0.00% |
| ROE | -19.35% | -306.61% |
| ROIC | -19.47% | -317.86% |
Growth (annualized)
| Metric | ALT | NVCT |
|---|---|---|
| Revenue CAGR (5Y) | -65.38% | N/A |
| Total return CAGR (5Y) | -25.30% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.